BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global (San Antonio, TX USA), and  CELLforCURE, part of SEQENS Group (Les Ulis, France), are proud to announce a partnership dedicated to  supporting the development and large-scale production of Advanced Therapy Medicinal Products  (ATMPs). 

This collaboration establishes a transatlantic connection enabling U.S. companies to leverage  CELLforCURE’s manufacturing capabilities in Europe, while European companies can benefit from BBG  Advanced Therapies’ production capacities in the U.S. Together, they provide enhanced global CDMO  capacity and an integrated service network to support the development and manufacturing needs of  ATMP developers.  

BBG Advanced Therapies integrates cell and tissue expertise with cutting-edge biomanufacturing  capabilities, which include a strong track record in MSC-based projects as well as adherence to relevant  FDA, EMA, and PMDA regulations. Supporting innovators with progressing early-stage development through late-phase readiness and market launch, BBGAT’s holistic ecosystem of services spans  leukapheresis, donor management, testing, cryopreservation, biomanufacturing and assay development,  all under a unified Quality Management System. BBGAT has 9 cGMP cleanrooms spanning over 558 m2 (6,000 sq. ft.) and a process development space spanning over 232 m2(2,500sq. ft.). With an eye toward  advancing the industry and expanding patient access, BBGAT also maintains the world’s only mobile  leukapheresis center. 

CELLforCURE, EMA-authorized and FDA-compliant, combines a unique blend of CDMO heritage and  proven commercial manufacturing expertise from Phase I to full-scale commercial production. Its “one stop-shop” facility spans 10,000 m², including 3,000 m² (32 291 sq. ft.) of GMP-certified areas across 7  independent manufacturing lines, each with 8 cleanrooms, ensuring maximum safety and compliance for  every product. CELLforCURE has a strong track record in CAR-T manufacturing as well as immune cells  therapies, standing as a trusted, comprehensive solution provider. The company enables seamless project  development by leveraging in-house Quality Control for 90% of processes, ensuring high-quality drug  product delivery. 

United by a shared vision to remove barriers in ATMPs manufacturing solutions, this collaboration creates  a fully scalable, global CDMO partnership between USA and Europe that accelerates the journey from  concept to commercialization. By combining transatlantic expertise and infrastructure, the partnership  enables therapy developers to scale rapidly, launch multinational trials, and reach patients more  effectively. Together, BBG Advanced Therapies and CELLforCURE now offer state-of-the-art GMP  manufacturing space, providing unmatched capacity to support global clients.